Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.

Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.

NCT Number	NCT07029230
Lead Sponsor	Martin Schweiger Collaborators: University Children's Hospital, Zurich
Conditions	Congenital Heart Surgery, Congenital Heart Disease in Children, Fontan Physiology
Enrollment	225 participants
Start Date	2025-09-10
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-17